Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for ...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...
- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbrevi...
H2 Global Group is strengthening its position as a European technology group connecting capital with clinically validated healthcare innovations. A prime...
The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...
Global pharma major Lupin Limited (Lupin) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pha...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopath...
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled wit...
Meiji Seika Pharma Co., Ltd. announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company deve...
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinner...
HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
© 2026 Biopharma Boardroom. All Rights Reserved.
